Shanghai Runda Medical Technology Co., Ltd. Class A

Shanghai Runda Medical Technology Co., Ltd. Class A

SSSE:603108
9.03
CNY
-0.51
(-5.35%)
-0.90EPS
6.03BMarket Cap
Apr 28Next Earn
Shanghai Runda Medical Technology Co., Ltd. Class A
SSE:603108
(Shanghai Stock Exchange)

Recent

price

9.03

P/E

ratio

- -

div

yld

4.39%

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.76
2.02
2.68
3.58
3.55
4.28
7.49
10.25
12.08
12.21
15.38
18.09
15.73
13.53
11.61
10.83
Revenue per Share
0.15
0.15
0.18
0.2
0.2
0.23
0.38
0.45
0.53
0.57
0.66
0.72
0.47
0.09
-0.91
-0.93
Basic EPS, GAAP
- -
-0.03
-0.14
-0.24
-1
-0.82
-0.75
0.47
-0.07
-0.01
0.12
-1.21
0.7
0.68
0.64
- -
Free Cash Flow per Basic Share
0.01
0.02
0.05
0.09
0.09
0.15
0.19
0.39
0.45
0.39
0.47
0.42
0.65
0.55
0.47
0.4
Dividend per Share
0.75
0.89
1.06
1.25
1.82
3.65
3.95
4.41
4.76
5.53
5.97
6.71
7.17
7.21
6.27
5.96
Book Value per Share
0.74
0.85
1
1.18
1.76
2.76
1.01
1.5
1.7
2.33
2.58
3.16
3.67
3.77
3.17
2.85
Tangible Book Value per Share
359
383
382
379
459
506
577
582
584
579
576
580
581
614
603
602
Basic Weighted Avg Shares
631
772
1,026
1,359
1,629
2,165
4,319
5,964
7,052
7,069
8,860
10,494
9,147
8,312
6,999
6,522
Sales/Revenue/Turnover
12.5
10.91
10.73
9.95
10.6
10.68
12.41
13.65
12.45
11.4
11.37
11.6
9.22
7.99
2.92
4.11
Operating Margin (%)
- -
17
27
46
71
104
154
209
239
303
365
384
375
394
361
- -
Depreciation Expense
54
59
68
75
92
116
219
262
310
330
380
418
273
55
-548
-559
Net Income, GAAP
25.63
27.71
26.28
27.14
26.61
26.41
23.11
27
25.46
20.76
23.35
20.07
32.48
45.17
- -
- -
Effective Tax Rate (%)
8.63
7.61
6.62
5.53
5.63
5.38
5.08
4.39
4.39
4.67
4.29
3.98
2.99
0.67
-7.84
-8.57
Profit Margin (%)
223
244
250
243
486
1,069
648
778
423
652
1,260
1,310
1,866
1,659
838
237
Working Capital
- -
- -
- -
46
6
113
1,112
559
129
552
1,336
931
1,191
961
708
303
LT Debt
284
340
404
476
929
2,222
2,749
3,198
3,516
4,080
4,392
5,010
5,447
5,604
4,881
4,549
Total Equity
- -
12.82
11.75
9.37
7.6
5.15
6.38
7.53
8.35
6.74
6.43
6.07
3.75
1.64
- -
- -
Return on Invested Capital (%)
- -
15.66
14.09
12.89
10.01
5.55
4.88
4.04
4.56
4.58
4.03
3.96
2.75
0.75
- -
- -
Return on Capital (%)
- -
18.83
18.25
17.09
13.11
7.66
9.95
10.82
11.65
11.07
11.41
11.37
6.69
1.28
-13.47
-14.29
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
6,079
5,883
5,347
LT Borrowings
504
362
236
LT Finance Leases
86
73
66
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
604
605
605
Market Capitalization
7,625
5,381
6,028

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
8,165
7,860
7,552
Cash, Cash Equivalents & STI
970
782
718
Accounts Receivable, Net
4,394
4,341
4,184
Inventories
1,575
1,610
1,513
Total Current Liabilities
7,547
7,382
7,315
Payables & Accruals
- -
- -
- -
ST Debt
6,079
5,883
5,347
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
22.58%
4.08%
-12.9%
Free Cash Flow
-255.23%
-437.85%
-7.43%
Net Income, GAAP
-102.19%
-236.25%
-1,092.02%
Sales/Revenue/Turnover
19.5%
1.2%
-15.8%
Total Cash Common Dividend
28.09%
7.52%
-16.6%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,072
2,063
2,041
2,135
8,312
2025
1,662
1,809
- -
1,730
6,999
2026
1,511
1,683
1,598
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.11
-0.07
0.01
0.09
2025
-0.11
-0.09
- -
-0.64
-0.91
2026
-0.09
-0.06
-0.14
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
0.06
0.24
0.11
0.55
2025
0.09
0.11
- -
0.1
0.47
2026
0.09
0.13
0.08
- -
- -
Business
Shanghai Runda Medical Technology Co., Ltd. delivers comprehensive medical laboratory solutions throughout China. The company furnishes a suite of offerings including platform deployment, laboratory layout and modernization, adherence to standardization protocols, and sophisticated information management systems. They also provide medical diagnostic tools for professionals across areas such as biochemistry, diabetes management, point-of-care testing, immunoassay analysis, and molecular biology. Complementing these are specialized technical assistance and efficient logistical support. Established in 1999, the firm maintains its principal operations in Shanghai, China, and has expanded its footprint to include over 50 subsidiaries, providing integrated services to more than 4,000 public medical institutions. Notably, in 2022, the company formed a joint venture with QuidelOrtho to develop and manufacture assays for the VITROS® platform within China, further enhancing its in-vitro diagnostics capabilities.